HIV pre-exposure prophylaxis could help 1.2 million in USBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6384 (Published 25 November 2015) Cite this as: BMJ 2015;351:h6384
- Michael McCarthy
More than 1.2 million people in the United States are at high enough risk for HIV infection to be candidates for daily oral pre-exposure prophylaxis (PrEP) but most are not receiving the treatment, officials at the US Centers for Disease Control and Prevention (CDC) said on 24 November.
Currently, the CDC recommends the combination of two antiretroviral drugs, tenofovir disoproxil fumarate and emtricitabine, taken in a single pill daily to prevent HIV in people at high risk for the infection. This combination, marketed in the US as Truvada, was approved for PrEP …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial